OrthoPediatrics Q3 revenue rises, beats estimates

Overview

• US pediatric orthopedics device maker's Q3 revenue rose 19% yr/yr, beating analyst expectations

• Q3 adjusted EBITDA grew yr/yr

• Company raised full-year 2026 revenue guidance

Outlook

• OrthoPediatrics raises 2026 revenue guidance to $270 mln-$273 mln from $265 mln-$269 mln

• Company expects 2026 adjusted EBITDA of about $25 mln and breakeven free cash flow

• Company expects new product launches to drive financial performance in coming years

Result Drivers

• TRAUMA & DEFORMITY GROWTH - Co said Q3 revenue growth was mainly driven by global Trauma and Deformity and OPSB product sales

• HIGHER PROCEDURE VOLUMES - Co attributed Q3 growth to increased procedure volumes

• PRODUCT EXPANSION - Co cited new and expanded product lines, including Cannulated Screws, PNP Femur, PediPlates, 3P Hip, and OPSB, as drivers of Trauma & Deformity revenue

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for OrthoPediatrics Corp is $25.00, about 4.1% above its October 26 closing price of $24.02

Reuters Recommended Reads

• Oct 27 - Repligen Q3 revenue beats estimates on higher demand; lifts outlook

• Oct 27 - Pharming Group Q3 revenue rises on US demand; tightens guidance

• Oct 27 - Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)